Interlune has received $15M in funding to develop a scalable supply of Helium-3 from the lunar surface.

Eckert & Ziegler and Nucleus RadioPharma have signed an agreement to address the increasing demand for Lu-177 and Ac-225.

The German manufacturer and Canadian drug developer are partnering to address the supply crunch of radioisotopes.

Actinium-225 remains in short supply, slowing drug research.

The new facility is run by Novartis and is being called the “most advanced of its kind."

Supply chain disruptions are blamed for the lack of production.

Outdated infrastructure and a lack of young people entering the field are both impacting the security of critical isotopes such as molybdenum-99.

The company’s CEO, Greg Piefer, detailed the plans at the Wisconsin Entrepreneurs’ Conference on June 2, stating that production would be achieved via small-scale nuclear transmutation.